MET and hepatocellular carcinoma: Those findings have indicated that Indo5 is associated with marked suppression of HCC cells co-expressing c-Met and Trks, which supports the clinical development of Indo5 as an antitumor treatment for HCC patients with co-active c-Met and Trks signaling.